1592 related articles for article (PubMed ID: 27334978)
1. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
3. The Role of Molecular Diagnostics in the Management of Patients with Gliomas.
Wirsching HG; Weller M
Curr Treat Options Oncol; 2016 Oct; 17(10):51. PubMed ID: 27501915
[TBL] [Abstract][Full Text] [Related]
4. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
5. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
7. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
9. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
Di Stefano AL; Enciso-Mora V; Marie Y; Desestret V; Labussière M; Boisselier B; Mokhtari K; Idbaih A; Hoang-Xuan K; Delattre JY; Houlston RS; Sanson M
Neuro Oncol; 2013 May; 15(5):542-7. PubMed ID: 23161787
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers in adult gliomas: the present and the future.
Thomas L; Di Stefano AL; Ducray F
Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
[TBL] [Abstract][Full Text] [Related]
11. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
12. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
13. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
14. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
15. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
16. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathology of tumors of the central nervous system.
Kristensen BW; Priesterbach-Ackley LP; Petersen JK; Wesseling P
Ann Oncol; 2019 Aug; 30(8):1265-1278. PubMed ID: 31124566
[TBL] [Abstract][Full Text] [Related]
18. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
19. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
20. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
